Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicentric prospective dose-finding and phase II study of oral topotecan in recurrent small-cell lung cancer
2009-015296-26Phase 2Active
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan in small cell lung cancer (SCLC), sponsored by Azienda USL Toscana Nord Ovest. Primary endpoints: Activity of oral topotecan treatment and Safety profile. Started Dec 2009; status: active.
02
Drugs
topotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2009-015296-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015296-26.